Biomarker Helps Predict Death Risk in Coronary Angiography
Myeloperoxidase and C-reactive protein show independent and combined predictive value
TUESDAY, March 9 (HealthDay News) -- Myeloperoxidase (MPO) predicts the risk of cardiovascular mortality in patients who undergo coronary angiography, and considering MPO and C-reactive protein (CRP) together may be useful for long-term risk assessment, according to research published in the March 16 issue of the Journal of the American College of Cardiology.
Claire L. Heslop, of St. Paul's Hospital in Vancouver, Canada, and colleagues analyzed data from 885 selective coronary angiography patients who had stable angina, earlier myocardial infarction, aortic stenosis or regurgitation, or mitral valve regurgitation. Subjects provided blood samples before angiography and were followed for a median of 12.9 years for cardiovascular mortality.
MPO predicted angiographic coronary artery disease, the researchers found. The predicted risk for cardiovascular mortality was 2.4-fold in the top tertile of MPO compared to the bottom. Patients with elevated levels of either MPO or CRP had a 5.3-fold higher risk of cardiovascular mortality compared to those in the lowest tertile of both markers. However, subjects with elevated levels of both markers had a 4.3-fold risk compared to those with an elevated level of either marker.
"The oxidative stress biomarker MPO powerfully enhances cardiovascular risk prediction, and is additive with CRP for predicting risk in selective angiography patients. Future studies are essential to demonstrate whether outcomes may be improved when MPO and CRP measurements are utilized together for prognostic assessment and therapeutic decision making," the authors conclude.